Embozene
Payments companies reported to CMS as associated with Embozene. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Embozene, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Embozene
These are the largest totals companies reported as associated with Embozene. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jessica Stewart | Los Angeles, CA | Vascular & Interventional Radiology | $8,327.62 |
| Alexander Kim | Oxon Hill, MD | Vascular & Interventional Radiology | $6,501.20 |
| Jeremy Kim | Charlotte, NC | Vascular & Interventional Radiology | $6,346.33 |
| Rahul Patel | New York, NY | Vascular & Interventional Radiology | $6,200.66 |
| Charles Nutting | Greenwood Village, CO | Vascular & Interventional Radiology | $2,377.60 |
| Samdeep Mouli | Nashville, TN | Vascular & Interventional Radiology | $1,228.37 |
| Quinn Meisinger | San Diego, CA | Vascular & Interventional Radiology | $321.53 |
| Mchael Vitale | Lake Success, NY | Vascular & Interventional Radiology | $302.26 |
| Isabel Newton | San Diego, CA | Vascular & Interventional Radiology | $282.25 |
| Kevin Burns | Orange, CA | Vascular & Interventional Radiology | $253.24 |
Prescribed Embozene?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.